Pharmaceutical tablets

Abstract

The present invention relates to novel pharmaceutical tablets useful for administering pharmaceutical active ingredients, such as bisphosphonates. These tablets have improved surface properties which can aid esophageal transit, thereby reducing the potential for adverse gesture intestinal effects. The present invention also relates to processes for making said novel pharmaceutical tablets.

What is claimed is:  
     
         1 . A pharmaceutical tablet, comprising: 
 (a) from about 0.5 to 40% by weight of an active ingredient selected from the group consisting of a bisphosphonic acid or a pharmaceutically acceptable salt or ester thereof; and    (b) from about 60 to 99.5% by weight of excipients, said excipients comprising a diluent selected from the group consisting of anhydrous lactose or hydrous fast flow lactose, or mixtures thereof, a binder, a disintegrant, a lubricant; and a wax.    
     
     
         2 . A pharmaceutical tablet according to    claim 2    wherein said wax is selected from the group consisting of apple peel wax, avocado wax, bayberry wax, beeswax, candelilla wax, carnauba wax, ceresin, cetyl esters, hydrogenated jojoba oil, hydrogenated jojoba wax, hydrogenated microcyrstalline wax, hydrogenated rice bran wax, hydrolyzed beeswax, jojoba butter, jojoba esters, jojoba wax, lanolin wax, microcrystalline wax, mink wax, montan acid wax, montan wax, orange peel wax, ouricury wax, oxidized beeswax, oxidized micorcrystalline wax, ozokerite, palm kernel wax, paraffin wax, paraffin, PEG-6 beeswax, PEG-8 beeswax, Peg-12 beeswax, PEG-20 beeswax, PEG-12 carnauba, potassium oxidized microcrystalline wax, rice wax, shellac wax, spent grain wax, sulfurized jojoba oil, synthetic beeswax, synthetic candelilla wax, synthetic carcauba, synthetic japan wax, synthetic jojoba oil, synthetic wax, and mixtures thereof.  
     
     
         3 . A pharmaceutical tablet according to    claim 3    wherein said bisphosphonic acid is selected from the group consisting of 
 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;  
 N-methyl-4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;  
 4-(N,N-dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid;  
 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid;  
 3-(N,N-dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid;  
 1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-bisphosphonic acid;  
 1-hydroxy-2-[3-pyridyl]ethylidene-1,1-bisphosphonic acid; and  
 4-(hydroxymethylene-1,1-bisphosphonic acid)piperidene;  
 or a pharmaceutically acceptable salt or ester thereof.  
 
     
     
         4 . A pharmaceutical tablet according to    claim 3    wherein said bisphosphonic acid is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or a pharmaceutically acceptable salt thereof.  
     
     
         5 . A pharmaceutical tablet according to    claim 4    wherein said bisphosphonic acid is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate.  
     
     
         6 . A pharmaceutical tablet according to    claim 5    wherein said diluent is anhydrous lactose, said binder is microcrystalline cellulose, said disintegrant is croscarmellose sodium, and said lubricant is magnesium stearate.  
     
     
         7 . A pharmaceutical tablet according to    claim 1    wherein said wax is present as a discontinuous wax polish.  
     
     
         8 . A pharmaceutical tablet according to    claim 7    wherein said wax is carnauba wax.  
     
     
         9 . A pharmaceutical tablet according to    claim 8    comprising from about 5 mg to about 70 mg, on a bisphosphonic acid active basis of said bisphosphonic acid.  
     
     
         10 . A process for the preparation of a pharmaceutical tablet comprising; 
 (a) forming a mixture by mixing an active ingredient selected from the group consisting of a bisphosphonic acid or a pharmaceutically acceptable salt or ester thereof, with a diluent, selected from the group consisting of anhydrous lactose or hydrous fast flow lactose, or mixtures thereof, a dry binder, a disintegrant, and optionally one or more additional ingredients selected from the groups consisting of: compression aids, flavors, flavor enhancers, sweeteners and preservatives;    (b) lubricating the mixture with a lubricant;    (c) compressing the resultant lubricated mixture into a desired tablet form; and    (d) coating the desired tablet with a wax to form a discontinuous wax polish.    
     
     
         11 . A process according to    claim 10    wherein said wax is selected from the group consisting of apple peel wax, avocado wax, bayberry wax, beeswax, candelilla wax, carnauba wax, ceresin, cetyl esters, hydrogenated jojoba oil, hydrogenated jojoba wax, hydrogenated microcyrstalline wax, hydrogenated rice bran wax, hydrolyzed beeswax, jojoba butter, jojoba esters, jojoba wax, lanolin wax, microcrystalline wax, mink wax, montan acid wax, montan wax, orange peel wax, ouricury wax, oxidized beeswax, oxidized micorcrystalline wax, ozokerite, palm kernel wax, paraffin wax, paraffin, PEG-6 beeswax, PEG-8 beeswax, Peg-12 beeswax, PEG-20 beeswax, PEG-12 camauba, potassium oxidized microcrystalline wax, rice wax, shellac wax, spent grain wax, sulfurized jojoba oil, synthetic beeswax, synthetic candelilla wax, synthetic carcauba, synthetic japan wax, synthetic jojoba oil, synthetic wax, and mixtures thereof.  
     
     
         12 . A process according to    claim 11    wherein said bisphosphonic acid is selected from the group consisting of 
 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;  
 N-methyl-4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;  
 4-(N,N-dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid;  
 3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid;  
 3-(N,N-dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid;  
 1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-bisphosphonic acid;  
 1-hydroxy-2-[3-pyridyl]ethylidene-1,1-bisphosphonic acid; and  
 4-(hydroxymethylene-1,1-bisphosphonic acid)piperidene;  
 or a pharmaceutically acceptable salt or ester thereof.  
 
     
     
         13 . A process according to    claim 12    wherein said bisphosphonic acid is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or a pharmaceutically acceptable salt thereof.  
     
     
         14 . A process according to    claim 13    wherein said bisphosphonic acid is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate  
     
     
         15 . A process according to    claim 14    wherein said diluent is anhydrous lactose, said binder is microcrystalline cellulose, said disintegrant is croscarmellose sodium, and said lubricant is magnesium stearate.  
     
     
         16 . A process according to    claim 15    wherein no additional water is added to the mixture prior to compressing.  
     
     
         17 . A process according to    claim 16    wherein said process is carried out at ambient temperature  
     
     
         18 . The process according to    claim 17    wherein the discontinuous wax polish is carnauba wax.